Home / Who We Are / The Foundry Team / Allan R. Will
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  The Foundry Team
   
 
Hanson S. Gifford, III
Kara Liebig
Karun D. Naga
Steven Kim
Mark E. Deem
Allan R. Will
Hank A. Plain, Jr.
Allan R. Will
Executive Chairman, EBR Systems, Inc.
Chairman, Setpoint Medical
Founder, The Foundry, LLC

Allan Will is an operating executive with extensive experience founding, funding, operating, and selling medical device companies. Will currently serves as CEO of EBR Systems, Chairman of the Board of Fractyl Labs (novel endoscopic treatment for Type 2 Diabetes) and Setpoint Medical (neurostimulation for debilitating inflammatory diseases) and director at the Fogarty Institute for Innovation. As Chairman of Ardian, Will led negotiation of the company’s acquisition by Medtronic, one of the largest venture-funded medical device company acquisitions in history. Formerly Will was a founding Managing Director in Split Rock Partners’ (SRP) Silicon Valley venture capital office, focusing on the therapeutic medical device field. Will joined Split Rock’s predecessor entity SPVC in 2002 after more than twenty years in operating roles, the last 17 as CEO of various Bay-area venture backed start-ups. Most recently, Will was Founder, Chairman and CEO of The Foundry, an incubator dedicated to transforming medical device concepts into companies where he co-founded 11 companies including Ardian, Evalve and Concentric Medical. Prior to The Foundry, Will was CEO of AneuRx, founded by Thomas Fogarty, M.D. to develop stent grafts for aortic aneurysms. During this three-year period, Will led AneuRx to make up three years on the competition, successfully launching in Europe simultaneously with the recognized market leader. AneuRx was acquired by Medtronic in 1996, growing to >$150MM one year post-launch to capture an 80% market leadership position. During this period Will and Dr. Fogarty co-founded Adjacent Surgical, sold to General Surgical Innovations in 1996. In 1994, Will led a $2 billion leveraged buyout attempt of the Eli Lilly cardiovascular device businesses, which later became Guidant Corporation. Previously, Will was President and CEO of Devices for Vascular Intervention (DVI), a company founded by John Simpson, MD, PhD to develop atherectomy devices. Will joined DVI in 1986 when the company consisted of 16 employees and over eight years grew the business to more than 500 employees, $100MM revenue run rate and 30% EBIT. Eli Lilly and Company acquired DVI in 1989. Prior to DVI, Will worked for Abbott Laboratories in various business development, marketing and general management capacities.

Mr. Will is an inventor on over 30 issued patents. He earned his M.S. in management at the Massachusetts Institute of Technology in 1981 and his B.S. in zoology from the University of Maryland in 1976.  Will is a University of Maryland Distinguished Alumnus and has served on the MIT Entrepreneurship Center Shareholders Board and the University of Maryland’s President’s Committee on Innovation and Entrepreneurship. In 2008, Astia (fka the Women’s Technology Cluster) named Will as the recipient of the Deloitte Leadership in Mentoring Award for mentoring women executives.

  © 2001-2019 The Foundry, LLC. All rights reserved. The Foundry is a registered trademark of The Foundry, LLC.